1. Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends

    By Lara Goldstein Psychedelics healthcare company Numinus Wellness (OTCQX: NUMIF ) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024. Q2 showed: Cash position of $4.8 (CA$6.6) million by February 29, 2024, c
  2. Two Top Biotechs Forge MDMA Supply Deals For Clinical Research

    By Lara Goldstein Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC: MDXXF ) with Numinus Wellness (OTC: NUMIF ) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX: OPTHF ) with Tel Aviv University for MDMA’s potential effects on addiction
  3. Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions

    By Lara Goldstein Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024. The program, open to providers at the University of Utah H
  4. Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More

    By Lara Goldstein Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have
  5. Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More

    By Lara Goldstein New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of sug